TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8029807
Drug: 600 or
Normalized name: MST 600 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 or 1200 mg aspirin (single dose)
Study: 1079063
Drug: 25 percent
Normalized name: METHYL SALICYLATE 250 mg in 1 mL TOPICAL CREAM [Methyl Salicylate 25 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 percent component therapy (Group 3)
Study: 1079063
Drug: Component therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component therapy
Study: 26468956
Drug: Twice-per-day dosing
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-per-day dosing regimen
Study: 16215339
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg preoperatively
Study: 3010707
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and hydrochlorothiazide combination therapy
Study: 22912445
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of colistine sulfate/kg of diet (antibiotic)
Study: 17324008
Drug: ISA 247
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA 247 (0.2 mg/kg bid)
Study: 17324008
Drug: ISA 247
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA 247 (0.3 mg/kg bid)
Study: 17324008
Drug: ISA 247
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA 247 (0.4 mg/kg bid)
Study: 17324008
Drug: ISA 247
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA 247 (mid dose)
Study: 11773574
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (200,000 IU, half that dose if <12 months)
Study: 2800986
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg/kg plus N2O/O2 (Group P, reference group)
Study: 50014
Drug: Facilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitation treatment approach
Study: 50014
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment approach
Study: 30932317
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 2.5 × 10^9 CFUs, once daily)
Study: 30624674
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNSs) containing 20 mg Fe/d until 6 mo postpartum, and SQ-LNSs for infants from 6 to 18 mo of age (LNS)
Study: 30624674
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNSs)
Study: 30624674
Drug: Iron (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (60 mg/d) and folic acid (IFA)
Study: 30624674
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MMN) containing 20 mg Fe/d until 6 mo postpartum
Study: 9590467
Drug: Brompheniramine 12
Normalized name: BROMPHENIRAMINE 12MG/PSEUDOEPHEDRINE 120MG CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompheniramine 12 mg twice daily
Study: 3398891
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus interferon (2 X 10(6) IU per square meter of body-surface area, daily for one week, then three times per week for one year)
Study: 28873709
Drug: Yacon syrup
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon syrup (8.74g of FOS/day)
Study: 28873709
Drug: Yacon syrup
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon syrup incorporated in yogurt
Study: 22964266
Drug: Mindfulness-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based therapy (MBT-AS)
Study: 20171048
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 15 mg/kg
Study: 20171048
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 10 mg/kg
Study: 20171048
Drug: Combined autologous
Normalized name: chondrocytes, autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined autologous and allogenic transfusion (Treatment groups)
Study: 18369313
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DVS
Study: 18369313
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DVS
Study: 18369313
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg DVS
Study: 18369313
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DVS
Study: 17235475
Drug: Combination preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination preparation (cinnarizine 20 mg and dimenhydrinate 40 mg)
Study: 17235475
Drug: Betahistine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (12 mg betahistinedimesilate)
Study: 10831147
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 microg daily via dry powder inhalation (Rotadisk)
Study: 16391172
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg clonidine
Study: 16391172
Drug: 0.1‐mg/h nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1‐mg/h nitroglycerin transdermal patch
Study: 14597946
Drug: Lisinopril (uptitrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (uptitrated to 20 mg/d)
Study: 14597946
Drug: Valsartan (uptitrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (uptitrated to 160 mg/d)
Study: 10759621
Drug: Extra strength
Normalized name: APAP Extra Strength
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra strength antacids
Study: 8752254
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium plus oral clodronate, 400 mg/day
Study: 8752254
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium plus oral clodronate, 400 mg/day for 30 days, followed by 60 days of calcium supplement alone (cyclical regimen)
Study: 8752254
Drug: Oral calcium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral calcium, 1000 mg/day (control)
Study: 8752254
Drug: Continuous clodronate
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous clodronate treatment
Study: 8752254
Drug: Cyclical clodronate
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical clodronate treatment
Study: 31668477
Drug: D1 agonist
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist (PF-06412562) 6 mg
Study: 31668477
Drug: D1 agonist
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist (PF-06412562) 15 mg
Study: 31668477
Drug: D1 agonist
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist (PF-06412562) 30 mg
Study: 31668477
Drug: D1 agonist
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist (PF-06412562) 6 mg, 15 mg, 30 mg
Study: 27288381
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen at a dose of 800 mg three times daily
Study: 24458801
Drug: Rosuvastatin (RSV)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (RSV) 10 mg/d
Study: 22573476
Drug: Rosuvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin plus Ezetimibe (RSV/EZT) 10 mg/d
Study: 20552577
Drug: Luteinizing-hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing-hormone-releasing hormone (LHRH) agonists for ovarian function suppression (OFS)
Study: 19399720
Drug: LHRH agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonists
Study: 18156478
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous 2% lignocaine eardrops
Study: 6401551
Drug: Slow sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow sodium tablets
Study: 14513587
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy combined with ultrasonic subgingival scaling and root planning (SRP)
Study: 8967666
Drug: 1.4 mg
Normalized name: phenol 1.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 mg of rhGH once daily plus placebo twice daily
Study: 8967666
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of rhIGF‐1 twice daily plus placebo once daily
Study: 8967666
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of rhIGF‐1 twice daily plus 1.4 mg of rhGH once daily
Study: 6275871
Drug: Neostigmine 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in hypercarbia group
Study: 6275871
Drug: Neostigmine 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in hypocarbia group
Study: 6275871
Drug: Neostigmine 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in normocarbia group
Study: 19884558
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT)
Study: 26940892
Drug: Zolpidem or
Normalized name: zolpidem Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem or Trazodone (second stage therapy)
Study: 26940892
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) or Cognitive therapy (CT) (second stage therapy)
Study: 26940892
Drug: Sleep parameters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep parameters from daily sleep diaries and polysomnography
Study: 26940892
Drug: Adverse events,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse events, dropout rates, treatment acceptability
Study: 24630938
Drug: L/L genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/L genotype
Study: 22089461
Drug: Civamide cream
Normalized name: Civamide
DrugBank: Zucapsaicin (DB09120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Civamide cream 0.075%
Study: 22089461
Drug: Civamide cream
Normalized name: Civamide
DrugBank: Zucapsaicin (DB09120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Civamide cream 0.01% (control)
Study: 11988188
Drug: Oral nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nitroglycerin 400 microg
Study: 7702049
Drug: r‐HuEPO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO treatment
Study: 45602
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine at 600 CCA
Study: 45602
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine at 200 CCA
Study: 45602
Drug: Whole-virus vaccine
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus vaccine at 200 CCA
Study: 25377429
Drug: Pregabalin 5
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 5 mg/kg/day
Study: 25377429
Drug: Pregabalin 10
Normalized name: pregabalin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 10 mg/kg/day
Study: 18379519
Drug: Local injections
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injections of tolperisone (midocalm) combined with tractional therapy, 3-6 injections
Study: 18379519
Drug: Tractional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tractional therapy without midocalm (placebo)
Study: 16116148
Drug: Peer-counseling program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-counseling program with up to six telephone calls from a trained childhood cancer survivor, tailored materials, and free nicotine replacement therapy
Study: 16080909
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (Viagra) 100 mg
Study: 9500298
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol and salmeterol
Study: 16575035
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg iv
Study: 4605245
Drug: Dummy injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy injection (Control)
Study: 24139323
Drug: Strongest Families
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strongest Families Smart Website intervention with weekly telephone coaching sessions
Study: 18326055
Drug: Kinematic outcome
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinematic outcome measures (e.g., peak hand velocity, endpoint error, reach extent, maximum shoulder flexion range of motion, minimum elbow extension range of motion)
Study: 6355314
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg, 10-day course, four times daily)
Study: 6355314
Drug: Rosaramicin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosaramicin (250 mg, 10-day course, four times daily)
Study: 30395052
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg·kg)
Study: 27079848
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IgG (M = 794.93; SD = 90.48)
Study: 27079848
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose IgG (M = 283.89; SD = 71.10)
Study: 24791643
Drug: Imagery Relief
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Relief Therapy (IRT)
Study: 17967668
Drug: Lidocaine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (0.5 mg/kg)
Study: 19560905
Drug: Procaine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine (0.5 mg/kg and 1.0 mg/kg)
Study: 18044436
Drug: Vaccination (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination (three doses at 3-week intervals)
Study: 2097484
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg epidural morphine in 2 ml saline
Study: 2097484
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg epidural morphine in 10 ml saline
Study: 2097484
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg epidural morphine in 20 ml saline
Study: 7027745
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of verapamil during standardized oral glucose load
Study: 7027745
Drug: oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral verapamil treatment after one week during standardized oral glucose load
Study: 7027745
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo during standardized oral glucose load
Study: 17209192
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gluten
Study: 22357413
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg for 12 weeks
Study: 22357413
Drug: Perindopril 10
Normalized name: amlodipine-perindopril 10 mg-14 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 10 mg for 12 weeks
Study: 17581448
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (MPH-IR) at doses of 0.1, 0.3, and 0.5 mg/kg twice daily for 2 weeks.
Study: 11756063
Drug: Sterol ester-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterol ester-1 (2.3 g plant sterol esters)
Study: 11756063
Drug: Stanol ester-1
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanol ester-1 (2.5 g plant stanol esters)
Study: 8267679
Drug: Bromfenac 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 50 mg
Study: 7937271
Drug: Bromfenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 100 mg
Study: 9690243
Drug: Bromfenac 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 200 mg
Study: 8106772
Drug: Pyrimethamine, 25
Normalized name: Pyrimethamine, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine, 25 mg thrice weekly
Study: 2669218
Drug: Prednisolone only
Normalized name: Prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone only series (60 mg daily for one month, then reduced to 20 mg on alternate days)
Study: 2669218
Drug: Cyclophosphamide-prednisolone series
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide-prednisolone series (100-120 mg cyclophosphamide daily plus 20 mg prednisolone on alternate days)
Study: 2669218
Drug: Death or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Death or failure of first treatment regimen
Study: 58317
Drug: Sampling cervix
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sampling cervix twice
Study: 31520538
Drug: Bite splint
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bite splint therapy
Study: 28074796
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser therapy (660 NM, spatial average energy fluency of 1.06 J/cm2)
Study: 19492956
Drug: 1-day application
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day application of topical 0.5% moxifloxacin, 4 times a day for 1 day, n = 63
Study: 15050762
Drug: ETT palpation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETT palpation and adjustment (Treatment)
Study: 17767063
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy group (diet control combined with aerobic exercises)
Study: 10394257
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of bisoprolol
Study: 10394257
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of verapamil LP
Study: 8893576
Drug: FUT‐175 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT‐175 (10 mg/L) during CPB
Study: 6350625
Drug: Tobramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1 mg. per kg. intramuscularly every 8 hours)
Study: 23666554
Drug: Benzylpiperazine (BZP)
Normalized name: cinnamido benzylpiperidinyl ethoxypropylbenzamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpiperazine (BZP) 200 mg
Study: 26912213
Drug: Dexamphetamine (DEX)
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (DEX) 20 mg
Study: 21342412
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg + Metformin 500 mg
Study: 21342412
Drug: Saxagliptin 10
Normalized name: Dapagliflozin/Saxagliptin 10 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 10 mg + Metformin 500 mg
Study: 15545304
Drug: Fenoldopam (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (selective dopamine-1 receptor agonist)
Study: 11751780
Drug: Once-daily (od)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (od) vancomycin
Study: 11751780
Drug: Twice-daily (bd)
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily (bd) vancomycin
Study: 8082348
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose bolus alteplase (n = 96)
Study: 8082348
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose 100 mg/2 h alteplase (n = 44)
Study: 10622071
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg b.d.
Study: 2530542
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.d.
Study: 31885300
Drug: Metronidazole combined
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole combined with debridement gel
Study: 31885300
Drug: Wet dressing
Normalized name: wet dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet dressing therapy combined with silver sulfadiazine
Study: 19750263
Drug: Extra parenteral
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra parenteral fluid therapy
Study: 16469617
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (25, 50, or 100 mg)
Study: 11096147
Drug: Increased erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased erythropoietin (Epo) at Hb levels falling below 10.5 g/dl (group A)
Study: 11096147
Drug: Increased erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased erythropoietin (Epo) at Hb levels falling below 11.5 g/dl (group B)
Study: 11096147
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in Epo dose at Hb levels above 12.0 g/dl (group C)
Study: 9415569
Drug: Ganciclovir (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (6 mg/kg once a day from day 1 to day 30, then 6 mg/kg once a day, Monday through Friday, until day 100)